Here are five key updates on AmSurg stock:
1. The current price target is $58.
2. Stock traded down 0.83 percent mid-day Monday, Dec. 29, hitting $54.75.
3. The company’s 52-week low is $40 and high is $55.61.
4. AmSurg has a market cap of $2.59 billion.
5. The company closed at $55.10 on Monday and opened at $54.89 on Tuesday, Dec. 30.
Third quarter revenue was up 91.3 percent from the same period in 2013, but still failed to meet estimates. Analysts predict AmSurg will post $2.64 earnings per share for the current fiscal year.
“Apart from strong performance of Sheridan, improved average revenues per procedure and increased same-center revenues were encouraging,” said a Zacks analyst, quoted in the report. “The Sheridan acquisition has paved AmSurg’s way into the huge and fast-growing fragmented physician outsourcing market. Nonetheless, headwinds like reduction in workers’ compensation reimbursement, sequestration and increased interest expense are intimidating.”
As a result, Zacks gave AmSurg a neutral rating.
More articles on surgery centers:
42 ASC financial facility statistics
8 observations on healthcare spending over the next 5 years
5 quick facts on Medical Facilities Corporation’s dividend report
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
